Passage Bio, Inc.
$6.25
▲
2.93%
2026-04-21 08:44:01
www.passagebio.com
NCM: PASG
Explore Passage Bio, Inc. stock price, valuation, financial statements, dividend history, analyst estimates, and long-term business fundamentals on StockSifting.
Market Cap
$37.44 M
Current Price
$6.25
52W High / Low
$20 / $5.12
Stock P/E
—
Book Value
$5.89
Dividend Yield
—
ROCE
-110.08%
ROE
-1.14%
Face Value
—
EPS
$-14.35
Exp Qtr EPS
—
Sector
Healthcare
Industry
Biotechnology
Employees
24
Beta
1.76
Debt / Equity
128.02
Current Ratio
2.07
Quick Ratio
2.07
Forward P/E
-1.12
Price / Sales
—
Enterprise Value
$9.43 M
EV / EBITDA
-0.22
EV / Revenue
—
Rating
Strong Buy
Target Price
$30.67
EPS Forecast (FY)
—
Pros
- Short-term liquidity looks comfortable.
- Valuation is not stretched on P/E basis.
Cons
- Return on equity is on the weaker side.
- Capital efficiency is modest.
- Operating margin is thin.
- Net margin is relatively low.
Sift Stocks
| S.No. | Name | Price | P.E. | Market Cap | Div Yld % | ROCE | ROE | 52Week High/ Low | Book Value |
|---|---|---|---|---|---|---|---|---|---|
| 1. | Arbutus Biopharma Corporation | $4.6 | — | $899.2 M | — | -30.53% | -38.52% | $5.1 / $2.94 | $0.4 |
| 2. | Replimune Group, Inc. | $2.07 | — | $170.93 M | — | -53.14% | -90.88% | $13.24 / $1.5 | $2.64 |
| 3. | Greenwich LifeSciences, Inc. | $24.52 | — | $384.32 M | — | -631.87% | -5.43% | $34.1 / $7.78 | $0.16 |
| 4. | Virax Biolabs Group Limited | $0.14 | — | $1.05 M | — | -107.11% | -83.82% | $1.2 / $0.1 | $0.81 |
| 5. | NeuroSense Therapeutics Ltd. | $0.71 | — | $25.1 M | — | -383.35% | -21.75% | $2.6 / $0.63 | $-0.05 |
| 6. | MediWound Ltd. | $17.35 | — | $226.34 M | — | -41.75% | -63.86% | $22.5 / $14.9 | $3.4 |
| 7. | Erasca, Inc. | $21.71 | — | $5.91 B | — | -35.74% | -33.27% | $19.78 / $1.06 | $1.14 |
Quarterly Results
Figures shown in M / B
| Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | |
|---|---|---|---|---|---|---|
| Sales | 0 M | 0 M | 0 M | 0 M | 0 M | — |
| Operating Profit | -10.34 M | -8.65 M | -10.33 M | -13.82 M | -14.27 M | — |
| Net Profit | -12.98 M | -7.75 M | -9.38 M | -15.4 M | -12.72 M | — |
| EPS in Rs | -4.05 | -2.42 | -2.93 | -4.8 | -3.97 | -6.15 |
Profit & Loss
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Sales | 0 M | 0 M | 0 M | 0 M |
| Operating Profit | -43.15 M | -65.17 M | -103 M | -135.39 M |
| Net Profit | -45.52 M | -64.77 M | -102.06 M | -136.12 M |
| EPS in Rs | -14.19 | -20.19 | -31.82 | -42.44 |
Balance Sheet
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Total Assets | 62.28 M | 102.41 M | 150.54 M | 243.55 M |
| Total Liabilities | 43.53 M | 41.15 M | 39.26 M | 42.18 M |
| Equity | 18.75 M | 61.26 M | 111.28 M | 201.37 M |
| Current Assets | 47.76 M | 78.81 M | 117.96 M | 197.04 M |
| Current Liabilities | 23.08 M | 19.36 M | 16.34 M | 18.35 M |
Cash Flow
Last available yearly cash flow history
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Operating CF | -31.51 M | -47.96 M | -78.26 M | -118.21 M |
| Investing CF | 40.22 M | 54.95 M | 65.24 M | 25.2 M |
| Financing CF | 0.02 M | 8.87 M | 0.14 M | -1.35 M |
| Free CF | -31.51 M | -47.99 M | -78.41 M | -123.48 M |
| Capex | — | -0.03 M | -0.15 M | -5.27 M |
5Y Margin & Growth History
Last 5 year derived history from yfinance annual statements
| 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|
| Revenue Growth % | — | — | — | — |
| Earnings Growth % | 36.54% | 25.02% | — | — |
| Profit Margin % | — | — | — | — |
| Operating Margin % | — | — | — | — |
| Gross Margin % | — | — | — | — |
| EBITDA Margin % | — | — | — | — |
Dividend & Split History
Latest dividend and stock split events stored from yfinance
Dividend History
No dividend history available.
Stock Splits
| Date | Split |
|---|---|
| 2025-07-14 | 1:0.05 |